Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib

Abstract We present the case of a 34‐year‐old Japanese man with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with lorlatinib resulted in a good intracranial r...

Full description

Bibliographic Details
Main Authors: Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:Thoracic Cancer
Subjects:
ALK
brigatinib
CNS penetration
lorlatinib
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.15395

Internet

https://doi.org/10.1111/1759-7714.15395

Similar Items